Medication use by JIA category reported at the last follow-up
| Medication | sJIA | PersOA | ExtOA | RF- PA | RF+PA | ErA | PsA | undiffA | P value* |
| n | 66 | 117 | 227 | 350 | 115 | 268 | 116 | 47 | |
| Females, % | 48.5 | 62.4 | 78.9 | 80.6 | 86.1 | 42.2 | 64.7 | 70.2 | |
| No of medicines per patient, mean (SD) (incl. DMARD) | 2.7 (2.5) | 1.7 (1.9) | 2.7 (2.2) | 2.4 (2.0) | 3.3 (2.3) | 2.1 (1.8) | 2.5 (2.0) | 2.3 (2.1) | <0.001 |
| Current treatment with DMARDs | 45 (68.2) | 53 (45.3) | 168 (74.0) | 210 (60.0) | 100 (87.0) | 161 (60.1) | 72 (62.1) | 27 (57.4) | <0.001 |
| bDMARDs | 39 (59.1) | 37 (31.6) | 145 (63.9) | 169 (48.3) | 84 (73.0) | 143 (53.4) | 61 (52.6) | 22 (46.8) | <0.001 |
| sDMARDs | 18 (27.3) | 29 (24.8) | 77 (33.9) | 98 (28.0) | 53 (46.1) | 57 (21.3) | 34 (29.3) | 11 (23.4) | <0.001 |
| NSAIDs | 24 (36.4) | 42 (35.9) | 118 (52.0) | 169 (48.3) | 63 (54.8) | 118 (44.0) | 64 (55.2) | 26 (55.3) | 0.008 |
| Systemic glucocorticoids | 21 (31.8) | 12 (10.3) | 53 (23.3) | 68 (19.4) | 40 (34.8) | 26 (9.7) | 22 (19.0) | 8 (17.0) | <0.001 |
| Analgesics | 8 (12.1) | 7 (6.0) | 24 (10.6) | 47 (13.4) | 16 (13.9) | 20 (7.5) | 12 (10.3) | 5 (10.6) | 0.198 |
| Opioid drugs | 6 (9.1) | 2 (1.7) | 9 (4.0) | 13 (3.7) | 4 (3.5) | 6 (2.2) | 2 (1.7) | 2 (4.3) | 0.181 |
| Drugs for acid related disorders | 4 (6.1) | 4 (3.4) | 18 (7.9) | 25 (7.1) | 8 (7.0) | 15 (5.6) | 9 (7.8) | 7 (14.9) | 0.314 |
| Antiinfectives for systemic use | 6 (9.1) | 5 (4.3) | 15 (6.6) | 25 (7.1) | 3 (2.6) | 15 (5.6) | 8 (6.9) | 3 (6.4) | 0.641 |
| Antidiarrheals, intestinal antiinflammatory/antiinfective agents | 2 (3.0) | 9 (7.7) | 10 (4.4) | 10 (2.9) | 9 (7.8) | 18 (6.7) | 3 (2.6) | 3 (6.4) | 0.127 |
| Thyroid therapy | 1 (1.5) | 3 (2.6) | 10 (4.4) | 20 (5.7) | 6 (5.2) | 11 (4.1) | 10 (8.6) | 3 (6.4) | 0.363 |
| Antidepressant drugs | 4 (6.1) | 3 (2.6) | 11 (4.8) | 10 (2.9) | 1 (0.9) | 12 (4.5) | 4 (3.4) | 0 | 0.319 |
| Antihypertensive drugs | 7 (10.6) | 1 (0.9) | 6 (2.6) | 10 (2.9) | 6 (5.2) | 4 (1.5) | 4 (3.4) | 3 (6.4) | 0.005 |
| Eye antiinfectives and antiinflammatory agents | 0 | 6 (5.1) | 4 (1.8) | 4 (1.1) | 0 | 9 (3.4) | 0 | 0 | 0.010 |
| Antiepileptic drugs | 0 | 0 | 8 (3.5) | 5 (1.4) | 1 (0.9) | 6 (2.2) | 0 | 0 | 0.082 |
| Psycholeptic drugs | 1 (1.5) | 1 (0.9) | 4 (1.8) | 2 (0.6) | 1 (0.9) | 7 (2.6) | 3 (2.6) | 0 | 0.444 |
| Antithrombotic agents | 3 (4.5) | 1 (0.9) | 2 (0.9) | 4 (1.1) | 4 (3.5) | 1 (0.4) | 0 | 0 | 0.027 |
| Drugs used in diabetes | 1 (1.5) | 1 (0.9) | 2 (0.9) | 3 (0.9) | 2 (1.7) | 2 (0.7) | 2 (1.7) | 1 (2.1) | 0.953 |
| Antiglaucoma preparations and miotics | 0 | 0 | 5 (2.2) | 0 | 0 | 2 (0.7) | 1 (0.9) | 0 | – |
| Drugs affecting bone structure and mineralisation | 0 | 0 | 1 (0.4) | 1 (0.3) | 0 | 0 | 0 | 0 | – |
| Lipid modifying agents | 1 (1.5) | 0 | 0 | 1 (0.3) | 0 | 0 | 0 | 0 | – |
The values are N (%) unless indicated otherwise.
*Univariable analysis of variance for continuously distributed parameters or χ2 test for categorical parameters.
bDMARD, biological DMARD; DMARD, disease-modifying antirheumatic drug; ErA, Enthesitis-related arthritis; ExtOA, Extended oligoarthritis; NSAIDs, non-steroidal antiinflammatory drugs; PersOA, persistent oligoarthritis; PsA, psoriatic arthritis; RF- PA, rheumatoid factor-negative polyarthritis; RF+ PA, RF-positive polyarthritis; sDMARD, synthetic DMARD; sJIA, systemic JIA; undiffA, undifferentiated arthritis.